Form 4: Artivion Director Jon Salveson Granted 6,325 Restricted Stock Awards

Artivion, Inc. director Jon W. Salveson was granted 6,325 shares of common stock as a Restricted Stock Award, vesting on May 22, 2026.

Summary

• Jon W. Salveson, a director of Artivion, Inc. (AORT), was granted 6,325 shares of common stock.
• The transaction occurred on May 22, 2025.
• The shares were acquired at a price of $0, indicating a grant rather than a cash purchase.
• Following this transaction, Mr. Salveson beneficially owns 129,840 shares of Artivion common stock.
• The grant is a Restricted Stock Award (RSA) and is scheduled to vest on May 22, 2026, pursuant to the terms of the company's Equity and Cash Incentive Plan.

Sentiment

Score: 6

Explanation: The grant of equity to a director is generally a positive signal as it aligns their interests with shareholders and incentivizes long-term performance. However, it's a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of Restricted Stock Awards to a director aligns management's interests with those of shareholders, as the value of the award is tied to the company's stock performance.
• It serves as an incentive for long-term performance and retention of key personnel.

Negatives

• The issuance of new shares, even as a grant, can lead to minor dilution for existing shareholders, though the amount here (6,325 shares) is likely negligible relative to the total outstanding shares.

Future Outlook

The vesting of the Restricted Stock Awards on May 22, 2026, indicates a future milestone related to the director's equity compensation, aligning their long-term incentives with company performance.

Management Comments

• The RSA Grant vests on May 22, 2026, pursuant to the terms of the Equity and Cash Incentive Plan.

Industry Context

This is a routine insider transaction, common across all industries, reflecting standard executive and director compensation practices involving equity incentives. It does not provide specific industry-wide insights beyond the general use of equity-based compensation.

Comparison to Industry Standards

• The grant of Restricted Stock Awards (RSAs) to directors is a common practice in publicly traded companies across various industries, including medical devices and healthcare technology, aligning director incentives with shareholder value creation. The specific size of the grant (6,325 shares) would need to be benchmarked against similar-sized companies and director compensation packages within the medical technology sector to assess its relative scale, but the mechanism itself is standard.

Related Party Transactions

• The grant of 6,325 shares of common stock to Jon W. Salveson, a director of Artivion, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially fostering long-term value creation. However, it also represents a minor dilution of existing shares, though typically negligible for such a grant size.
• Employees: While this specific grant is to a director, it reflects the company's broader equity incentive plan, which can positively impact employee retention and motivation if similar plans are available to other key personnel.

Next Steps

• The 6,325 Restricted Stock Awards granted to Jon W. Salveson are scheduled to vest on May 22, 2026.

Key Dates

Recommendation

Keywords

Artivion, AORT, SEC Form 4, Restricted Stock Award, RSA, Insider Transaction, Director Compensation, Equity Grant, Stock Ownership